Beamion LUNG-1 study results for zongertinib in treatment-naïve patients with HER2-mutant advanced NSCLC published in The New England Journal of Medicine
Posted May 19, 2026
Ridgefield, Conn. and Ingelheim, Germany. April 16, 2026 — Boehringer Ingelheim today announced that The New England Journal of Medicine (NEJM) published results from the Phase 1b Beamion LUNG-1 trial of HERNEXEOS® (zongertinib tablets) in treatment-naïve patients with advanced non-small cell lung cancer (NSCLC) who have HER2 activating mutations in the tyrosine kinase domain (TKD). The data in the manuscript,... Read More »
